Rosetta Genomics FGFR3 Mutation Assays

May 14, 2015

Rosetta Genomics said today that it will commercially launch two FGFR3 gene mutation assays next week at the American Urological Association annual meeting.

One assay is intended for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, while the other is intended to be used in conjunction with Ki67 expression to tissue-based prognostication at the initial diagnosis of bladder cancer. The microRNA tests are designed to be used in conjunction the company's FISH technology to help urologists better manage patients through improved prognostication and non-invasive recurrence monitoring, Rosetta said.

More Like This

Jul 19, 2018

Swift Biosciences 2S Turbo Library Kit

Swift Biosciences is now offering early access to its Swift 2S Turbo Library Kit. The kit enables the library prep workflow to be completed in two hours with as low as 1 nanogram of input. A range of sample types can be used, including fresh and fresh-frozen tissue, human or microbial genomic DNA, formalin-fixed paraffin-embedded samples, and PCR amplicons.

Jul 18, 2018

MNG Laboratories Comprehensive Intellectual Disability/Autism Panel

MNG Laboratories has added mitochondrial DNA sequencing and deletion analysis to its Comprehensive Intellectual Disability/Autism next-generation sequencing panel at no additional cost.

Jul 17, 2018

AMS Biotechnology CRISPR Complete Kits

AMS Biotechnology has released CRISPR-Cas9 editing kits for gene knockout, gene knock-in and gene mutation applications. The AMSBIO CRISPR Complete kits are made for specific projects by the company's genetic engineers and are available for almost any project type, including knockouts, knock-ins, point mutations, gene replacements, humanizations, tagging, and more. 

Custom-designed CRISPR Complete kits include crRNA custom-designed for the project, tracrRNA, Cas9 nuclease, and donor construct also custom-designed for the project. The donor construct may be provided as oligonucleotide or plasmid, depending on the project's needs.

Jul 17, 2018

Biocartis Idylla MSI Assay

Biocartis announced today that it has launched its automated Idylla MSI assay. The research-use-only assay provides information on the microsatellite instability-status of a tumor in about 150 minutes from one slice of FFPE tumor tissue without requiring a reference sample. The assay includes a set of seven MSI biomarkers, including ACVR2A, BTBD7, DID01, MRE11, RYR3, SEC31A, and SULF2 genes. 

Jul 13, 2018

Exosomics Siena SeleCTEV-DNA and SortEV-RNA

Exosomics Siena has launched its first proprietary liquid biopsy solutions, SeleCTEV-DNA and SortEV-RNA, which are both designed to aid selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum.

Unlike most liquid biopsy methods where total nucleic acids are harvested from blood Exosomics Siena's technology is based on the isolation and enrichment of tumor-derived exosomes. The new kits use unique affinity methods to select exosomes from which the DNA or RNA, respectively, can be extracted. Additionally, the SeleCTEV-DNA kit can be used to isolate circulating cell-free DNA in addition to DNA borne by exosomes.

Both tools are currently for research use only.

Jul 12, 2018

Medical and Biological Laboratories MEBRIGHT NUDT15 Kit

Medical and Biological Laboratories of Japan has launched the MEBRIGHT NUDT15 kit for detecting genetic polymorphisms in the NUDT15 (Nudix Hydrolase 15) gene, which can predict serious side effects of thiopurine drugs.

Thiopurine drugs are often prescribed to patients with inflammatory bowel disease, leukemia, rheumatic disease, or after an organ transplant, but clinical studies have shown that the drugs can induce adverse effects such as severe leukopenia and alopecia universalis within about eight weeks. A strong correlation has also been demonstrated between the development of serious adverse effects of thiopurine drugs and polymorphism in NUDT15, particularly among East Asians, Medical and Biological Laboratories said.

Using real-time PCR, the kit detects polymorphisms at codon 139 of NUDT15 in DNA from a patient's blood. The kit requires a processing time of two hours and simultaneously measures multiple samples, the firm said. The kit, which was jointly developed with Tohoku University, was approved as an in vitro diagnostic test by Japan's Pharmaceutical and Medical Device Agency in April.

Jul 11, 2018

Dante Labs Whole GenomeZ

Dante Labs has launched a whole-genome sequencing methodology called Whole GenomeZ. Whole GenomeZ provides 130X coverage to the entire exome and 30X coverage to the rest of the genome. The cost of the test is $999 or €849, which is below the standard cost of whole-genome sequencing at most facilities, the firm said. 

Jul 10, 2018

New England BioLabs NEBNext Direct Custom Ready Panels

New England Biolabs has launched the NEBNext Direct Custom Ready Panels, which allow users to design customized panels from a library of pre-synthesized baits for about 850 genes associated with a number of human diseases. The panels use the NEBNext Direct target enrichment technology, which hybridizes genomic DNA with biotinylated probes and converts the captured molecules into sequence-ready libraries. A unique molecular identifier tag is added to each DNA molecule prior to the final PCR amplification step. New England Biolabs said it will periodically update the panels to add new genes to the list and will update content corresponding to changes in gene definition and coordinates.

Jul 10, 2018

Ultivue UltiMapper Reagents

Ultivue has launched its UltiMapper portfolio of reagents for whole-slide protein biomarker spatial detection and analysis in tissue. More specifically, the company's UltiMapper I/O reagent kits are ready to use and enable profiling and characterization of tumor immuno-oncology markers in formalin-fixed, paraffin-embedded samples. Analysis can be conducted using instrumentation and software found in most immunohistochemistry laboratories, Ultivue said. The reagents are powered by Ultivue's InSituPlex technology, which combines DNA-barcoded antibodies with complementary fluorescent DNA barcodes.

Jul 06, 2018

Rheonix Literia PatternAlert Assay

Rheonix has launched its Listeria PatternAlert assay, a method to quickly identify molecular patterns from Listeria strains. The assay detects the presence or absence of independently occurring genetic targets that can sort Listeria strains into thousands of potential patterns. Each pattern generated by the assay covers a group of strains and can also include multiple species of Listeria. Running on the firm's Encompass Optimum platform, the assay provides results in six hours after a positive screen without requiring an isolate. The method will help food producers to identify and trace back sources of Listeria contamination, allowing users to minimize the risk of contamination and recall.

Jul 03, 2018

Devyser Thalassemia Kit

Devyser has released the Devyser Thalassemia kit for the analysis of sequence variants in the HBA1, HBA2, and HBB genes in human genomic DNA. Compatible with the Illumina MiSeq and MiniSeq instruments, the research-use-only kit detects all mutations in these genes including SNVs, indels, and copy number variations. The PCR chemistry provides complete and uniform coverage of targeted regions, and enables a high level of overlapping amplicon multiplexing and NGS library preparation with no sample splitting, the company said. 

Jul 02, 2018

WuXi NextCode LifeCode.ai

WuXi NextCode has launched LifeCode.ai, a health databank that uses blockchain technology to manage health data securely. The databank encrypts and stores user data multiple times, and the information can only be accessed with user-specific authorization, the firm said. In addition, each change in the data is recorded in a blockchain. WuXi has designed the databank for both individual and enterprise use.

Jun 28, 2018

Thermo Fisher Scientific Oncomine TCR Beta-SR Assay

Thermo Fisher Scientific has launched the Oncomine TCR Beta-SR Assay, a sequencing assay to characterize T-cell clonality in the tumor microenvironment. The test will interrogate the CDR3 region of the beta chain of the T-cell receptor, a region that is responsible for antigen recognition and helps to identify T-cell clones. The assay uses dual barcode indexing, which allows identification of low-frequency clones for potential tracking of minimal residual disease. It is optimized for formalin-fixed paraffin-embedded tissue, peripheral blood leukocytes, peripheral blood mononuclear cells, or cell-free DNA, and can work with either DNA or RNA as input.

Jun 25, 2018

Thermo Fisher Scientific Invitrogen TaqMan & SYBR Green Fast Advanced Cells-to-CT Kits

Thermo Fisher Scientific has launched Invitrogen TaqMan & SYBR Green Fast Advanced Cells-to-CT kits for real-time RT-PCR. The kits allow for a faster reverse transcriptase reaction and use a qPCR master mix system that is optimized to improve sensitivity to detect rare transcripts. They are designed for high-throughput gene expression analysis directly from cultured cells without RNA purification. The kits contain updated reverse transcription reagents for cDNA synthesis and faster TaqMan or SYBR Green master mixes for real-time PCR analysis.

Jun 25, 2018

Invitae Carrier Screen

Invitae has launched several genetic carrier screening products. The Invitae Comprehensive Carrier Screen uses next-generation sequencing to analyze 287 genes linked to serious genetic disorders and identifies more than 99 percent of disease-causing changes in most of the genes analyzed. In addition, the company offers a 46-gene test, called Invitae Broad Pan-Ethnic Carrier Screen, that assesses a smaller set of common disorders, and a test called Invitae Pan-Ethnic Carrier Screen that analyzes three genes associated with cystic fibrosis, spinal muscular atrophy, and fragile X syndrome. Both of the smaller panels can be supplemented with a customized set of genes from the large panel and with 13 genes not included in any pre-curated panel. The Invitae Carrier Screen replaces the GeneVu carrier screen from Good Start Genetics, which Invitae acquired last year.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
09
Sponsored by
Agena Bioscience

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.